HIGHLIGHTS
- who: Luisa Chocarro and colleagues from the Universidad Pu00fablica de (UPNA), Hospital Universitario de (HUN), Pamplona, Spain have published the article: Cutting-Edge CAR Engineering: Beyond T Cells, in the Journal: Biomedicines 2022, 10, 3035. of /2022/
- what: For primary outcome measures, the anti-tumour activity of the CAR-macrophages is compared against organoids from HER2 negative, HER2 low and HER2 positive breast cancers (for 24 months) and to non-modified macrophages (for 24 months).
- how: Similar results were obtained with anti-CD47/Siglec-10 therapies resulting in improved phagocytic abilities in macrophages . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.